Cost-Effectiveness Analysis of Sofosbuvir Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: An Analysis With Real World Outcomes From a Multicentre Cohort in Japan

BMJ Open - United Kingdom
doi 10.1136/bmjopen-2018-023405
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Related search

Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 3a in Pakistani Population - A Real World Experience

Pakistan Journal of Medical Sciences
Medicine
2019English

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Digestive Diseases and Sciences
PhysiologyGastroenterology
2016English

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost-Utility Analysis of Sofosbuvir for Treatment of Genotype2 Chronic Hepatitis C in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

JAMA - Journal of the American Medical Association
Medicine
2014English

An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C

Hepatitis Monthly
HepatologyInfectious Diseases
2015English

Daclatasvir and Sofosbuvir With Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients With Cirrhosis: A Phase III Study (ALLY-3C)

Antiviral Therapy
Infectious DiseasesPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy